GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Gross Margin %

OBI Pharma (ROCO:4174) Gross Margin % : -286.45% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. OBI Pharma's Gross Profit for the three months ended in Mar. 2024 was NT$-26.17 Mil. OBI Pharma's Revenue for the three months ended in Mar. 2024 was NT$9.14 Mil. Therefore, OBI Pharma's Gross Margin % for the quarter that ended in Mar. 2024 was -286.45%.


The historical rank and industry rank for OBI Pharma's Gross Margin % or its related term are showing as below:

ROCO:4174' s Gross Margin % Range Over the Past 10 Years
Min: -852.13   Med: -129.37   Max: 95.41
Current: -164.5


During the past 13 years, the highest Gross Margin % of OBI Pharma was 95.41%. The lowest was -852.13%. And the median was -129.37%.

ROCO:4174's Gross Margin % is ranked worse than
96.8% of 750 companies
in the Biotechnology industry
Industry Median: 60.91 vs ROCO:4174: -164.50

OBI Pharma had a gross margin of -286.45% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for OBI Pharma was 0.00% per year.


OBI Pharma Gross Margin % Historical Data

The historical data trend for OBI Pharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma Gross Margin % Chart

OBI Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -122.41 95.41 -136.32 -852.13 -176.89

OBI Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,076.60 -188.49 -187.00 -77.14 -286.45

Competitive Comparison of OBI Pharma's Gross Margin %

For the Biotechnology subindustry, OBI Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OBI Pharma's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where OBI Pharma's Gross Margin % falls into.



OBI Pharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

OBI Pharma's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-73.5 / 41.549
=(Revenue - Cost of Goods Sold) / Revenue
=(41.549 - 115.046) / 41.549
=-176.89 %

OBI Pharma's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-26.2 / 9.135
=(Revenue - Cost of Goods Sold) / Revenue
=(9.135 - 35.302) / 9.135
=-286.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


OBI Pharma  (ROCO:4174) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

OBI Pharma had a gross margin of -286.45% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


OBI Pharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of OBI Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


OBI Pharma (ROCO:4174) Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, Room. 1907, 19th Floor, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is part of the healthcare sector. The company and its subsidiaries are engaged in new drug research. Its focus is on the unmet medical need in challenging diseases throughout the world, such as cancer. OBI strives to improve health and the quality of life through cost-effective therapeutics. The Group has four reportable segments, which are the anti-cancer new drug segment, bispecific monoclonal antibody new drug segment, botulinum toxin new drug segment, and CDMO segment.

OBI Pharma (ROCO:4174) Headlines

No Headlines